Across TCGA pan-cancer cohorts, EEF1G Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EEF1G data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher EEF1G Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EEF1G expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
SARC, PRAD, and UCEC are the cancer types where EEF1G Mutation most reproducibly stratifies survival.